ASC30 vs Efmedaglutide alfa

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1 receptor · full Obesity pipeline

ASC30

Developed by Ascletis Pharma

Phase 3 in Obesitysmall molecule
Partial signal

NCT07002905 · Phase 2 · completed

The study randomly assigned 125 participants and used quadruple blinding with placebo control across seven cohorts. Its primary endpoint was percent change in body weight at Week 13, but the registry has not posted whether this endpoint was met.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: July 2028 · NCT07743463 (registry estimate)

Reported efficacy

Percent change in body weight from Baseline up to Week 13 (Baseline and Week 13): Placebo-adjusted mean weight loss at Week 13: 5.4% (20mg), 7.0% (40mg), 7.7% (60mg) ASC30, all p<0.0001 vs placebo (met)

Result source: NCT07002905

Efmedaglutide alfa · Shanmeining

Developed by TJ Biopharma Co., Ltd. and partners

Phase 3 in Obesityfusion protein
Partial signal

NCT05997576 · Phase 3 · completed

The study was randomized, double-blind, and placebo-controlled, with 675 participants and clinical primary outcomes measuring weight loss.

Result from CSPC's HKEX voluntary announcement of 13 October 2025 on the NMPA acceptance of the efmedaglutide alfa (TG103) application. The announcement names no trial number; the link to NCT05997576 rests on design and timing (the only TG103 Phase 3 trial in non-diabetic overweight or obesity, 675 participants, primary completion 17 February 2025).

Reported efficacy

Proportion of participants with weight loss of ≥ 5% at week 40 (From baseline to week 40); Relative percentage change from baseline in body weight at week 40 (From baseline to week 40): Body weight vs placebo in overweight or obese adults (pivotal Phase 3): CSPC states the product significantly reduced body weight compared with placebo; no figures released. The announcement does not report the co-primary proportion with at least 5% weight loss (CSPC announcement, 13 October 2025).

Result source: NCT05997576

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointASC30Efmedaglutide alfa
Body weight, % change—Trial running · NCT07743463—Not posted · NCT05997576
Weight loss of 5% or more—Trial running · NCT07743463—Not posted · NCT05997576
Weight loss of 10% or more—Trial running · NCT07743463—Not posted · NCT05997576
Waist circumference, change (cm)—Trial running · NCT07743463—Not posted · NCT05997576

Body weight, % change

ASC30
—Trial running · NCT07743463
Efmedaglutide alfa
—Not posted · NCT05997576

Weight loss of 5% or more

ASC30
—Trial running · NCT07743463
Efmedaglutide alfa
—Not posted · NCT05997576

Weight loss of 10% or more

ASC30
—Trial running · NCT07743463
Efmedaglutide alfa
—Not posted · NCT05997576

Waist circumference, change (cm)

ASC30
—Trial running · NCT07743463
Efmedaglutide alfa
—Not posted · NCT05997576
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Efmedaglutide alfa
Body weight vs placebo in overweight or obese adults (pivotal Phase 3): CSPC states the product significantly reduced body weight compared with placebo; no figures released. The announcement does not report the co-primary proportion with at least 5% weight loss (CSPC announcement, 13 October 2025). NCT05997576 · Phase 3 · design grade: moderate · publication or press release

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

ASC30

Weight 7.7% @ 13wk60mg ASC30
percent change · % of baseline
No placebo or comparator arm
NCT07002905 · Phase 2 · sponsor-reported, not registry data
show 2 more results
7% @ 13wk40mg ASC30
NCT07002905 · Phase 2 · sponsor-reported, not registry data
5.4% @ 13wk20mg ASC30
NCT07002905 · Phase 2 · sponsor-reported, not registry data

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

ASC30

Developed by Ascletis Pharma

Phase 3 in Type 2 Diabetessmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: July 2028 · NCT07743450 (registry estimate)

No aligned efficacy figure on record for this race.

Efmedaglutide alfa · Shanmeining

Developed by TJ Biopharma Co., Ltd. and partners

Phase 3 in Type 2 Diabetesfusion protein
Partial signal

NCT06235086 · Phase 3 · completed

This was a randomized, quadruple-masked Phase 3 trial with 632 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-09-30. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Reported efficacy

Changes in glycosylated hemoglobin (HbA1c) from baseline at 28 weeks of treatment (Baseline through Week28): Primary endpoint, HbA1c change at week 28: each TG103 dose non-inferior to dulaglutide 1.5 mg (treatment policy analysis); 15 mg lowered HbA1c 1.38% (CSPC, 2026-09-30). (met)

Result source: NCT06235086

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointASC30Efmedaglutide alfa
HbA1c, change—Trial running · NCT07743450—Not posted · NCT06258148
Body weight, change (kg)—Trial running · NCT07743450—Not posted · NCT06258148
HbA1c below 7%—Trial running · NCT07743450—Not posted · NCT06258148
Fasting plasma glucose, change—Trial running · NCT07743450—Not posted · NCT06258148
3-point MACE (% with event)—Trial running · NCT07743450—Not posted · NCT06258148

HbA1c, change

ASC30
—Trial running · NCT07743450
Efmedaglutide alfa
—Not posted · NCT06258148

Body weight, change (kg)

ASC30
—Trial running · NCT07743450
Efmedaglutide alfa
—Not posted · NCT06258148

HbA1c below 7%

ASC30
—Trial running · NCT07743450
Efmedaglutide alfa
—Not posted · NCT06258148

Fasting plasma glucose, change

ASC30
—Trial running · NCT07743450
Efmedaglutide alfa
—Not posted · NCT06258148

3-point MACE (% with event)

ASC30
—Trial running · NCT07743450
Efmedaglutide alfa
—Not posted · NCT06258148
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ASC30: no structured comparison results are available for Type 2 Diabetes.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Efmedaglutide alfa
Primary endpoint, HbA1c change at week 28: each TG103 dose non-inferior to dulaglutide 1.5 mg (treatment policy analysis); 15 mg lowered HbA1c 1.38% (CSPC, 2026-09-30). NCT06235086 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ASC30's landscape · Efmedaglutide alfa's landscape